Demographics and baseline disease characteristics by diagnosis
| Demographics and characteristics . | AITL, n = 13 . | PTCL, n = 22 . | All treated patients, N = 35 . |
|---|---|---|---|
| Median age, y (min, max) | 64 (55,79) | 64.5 (33, 83) | 64 (33, 83) |
| Male, n (%) | 10 (77) | 17 (77) | 27 (77) |
| Race, n (%) | |||
| White | 11 (85) | 18 (82) | 29 (83) |
| Black or African American | 2 (15) | 3 (14) | 5 (14) |
| Asian | 0 | 1 (5) | 1 (3) |
| Baseline ECOG performance status, n (%) | |||
| 0 | 2 (15) | 5 (23) | 7 (20) |
| 1 | 8 (62) | 15 (68) | 23 (66) |
| 2 | 3 (23) | 2 (9) | 5 (14) |
| Median time from diagnosis to first dose, mo (min, max) | 13.2 (3.2, 52.6) | 9.5 (1.1, 78.2) | 11.1 (1.1, 78.2) |
| CD30 expression* | |||
| Positive | 9 (69) | 17 (77) | 26 (74) |
| Negative | 2 (15) | 4 (18) | 6 (17) |
| NA or missing | 2 (15) | 1 (5) | 3 (9) |
| Stage at initial diagnosis, n (%) | |||
| I | 1 (8) | 0 | 1 (3) |
| II | 1 (8) | 1 (5) | 2 (6) |
| III | 5 (38) | 8 (36) | 13 (37) |
| IV | 3 (23) | 11 (50) | 14 (40) |
| Unknown | 3 (23) | 2 (9) | 5 (14) |
| Disease status relative to most recent prior therapy, n (%) | |||
| Refractory | 9 (69) | 13 (59) | 22 (63) |
| Relapsed | 4 (31) | 9 (41) | 13 (37) |
| Disease status relative to frontline therapy, n (%) | |||
| Refractory | 9 (69) | 17 (77) | 26 (74) |
| Relapsed | 4 (31) | 5 (23) | 9 (26) |
| Median number of prior cancer-related systemic therapy (min, max) | 3 (1, 4) | 2 (1, 9) | 2 (1, 9) |
| Patients with any prior cancer-related radiotherapy, n (%) | 1 (8) | 3 (14) | 4 (11) |
| Patients with prior autologous stem cell transplant, n (%) | 2 (15) | 1 (5) | 3 (9) |
| Demographics and characteristics . | AITL, n = 13 . | PTCL, n = 22 . | All treated patients, N = 35 . |
|---|---|---|---|
| Median age, y (min, max) | 64 (55,79) | 64.5 (33, 83) | 64 (33, 83) |
| Male, n (%) | 10 (77) | 17 (77) | 27 (77) |
| Race, n (%) | |||
| White | 11 (85) | 18 (82) | 29 (83) |
| Black or African American | 2 (15) | 3 (14) | 5 (14) |
| Asian | 0 | 1 (5) | 1 (3) |
| Baseline ECOG performance status, n (%) | |||
| 0 | 2 (15) | 5 (23) | 7 (20) |
| 1 | 8 (62) | 15 (68) | 23 (66) |
| 2 | 3 (23) | 2 (9) | 5 (14) |
| Median time from diagnosis to first dose, mo (min, max) | 13.2 (3.2, 52.6) | 9.5 (1.1, 78.2) | 11.1 (1.1, 78.2) |
| CD30 expression* | |||
| Positive | 9 (69) | 17 (77) | 26 (74) |
| Negative | 2 (15) | 4 (18) | 6 (17) |
| NA or missing | 2 (15) | 1 (5) | 3 (9) |
| Stage at initial diagnosis, n (%) | |||
| I | 1 (8) | 0 | 1 (3) |
| II | 1 (8) | 1 (5) | 2 (6) |
| III | 5 (38) | 8 (36) | 13 (37) |
| IV | 3 (23) | 11 (50) | 14 (40) |
| Unknown | 3 (23) | 2 (9) | 5 (14) |
| Disease status relative to most recent prior therapy, n (%) | |||
| Refractory | 9 (69) | 13 (59) | 22 (63) |
| Relapsed | 4 (31) | 9 (41) | 13 (37) |
| Disease status relative to frontline therapy, n (%) | |||
| Refractory | 9 (69) | 17 (77) | 26 (74) |
| Relapsed | 4 (31) | 5 (23) | 9 (26) |
| Median number of prior cancer-related systemic therapy (min, max) | 3 (1, 4) | 2 (1, 9) | 2 (1, 9) |
| Patients with any prior cancer-related radiotherapy, n (%) | 1 (8) | 3 (14) | 4 (11) |
| Patients with prior autologous stem cell transplant, n (%) | 2 (15) | 1 (5) | 3 (9) |
Per central laboratory.